Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One common respiratory ...

A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...

All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

RSV is a highly contagious virus that affects people of all ages, from infants to adults. Its symptoms often mimic those of ...

RSV, a common respiratory virus that usually causes mild, cold-like symptoms, is on the rise. While usually innocuous in adults, RSV cases in children and the elderly can be far more serious.

Administering the respiratory syncytial virus (RSV) in older adults with underlying health conditions may be a cost-effective ...

Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

The researchers found that RSV vaccines could significantly reduce the burden of disease and associated healthcare costs — but not all groups would benefit equally from a publicly funded program.